Matinas Biopharma (MTNB) Competitors $0.55 +0.03 (+5.96%) Closing price 04/1/2025 03:57 PM EasternExtended Trading$0.56 +0.01 (+1.81%) As of 04/1/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MTNB vs. PHXM, MBRX, BMRA, TRIB, NEUP, GOVX, SNSE, BLRX, GELS, and PRTGShould you be buying Matinas Biopharma stock or one of its competitors? The main competitors of Matinas Biopharma include PHAXIAM Therapeutics (PHXM), Moleculin Biotech (MBRX), Biomerica (BMRA), Trinity Biotech (TRIB), Neuphoria Therapeutics Inc. - Common Stock (NEUP), GeoVax Labs (GOVX), Sensei Biotherapeutics (SNSE), BioLineRx (BLRX), Gelteq (GELS), and Portage Biotech (PRTG). These companies are all part of the "pharmaceutical products" industry. Matinas Biopharma vs. PHAXIAM Therapeutics Moleculin Biotech Biomerica Trinity Biotech Neuphoria Therapeutics Inc. - Common Stock GeoVax Labs Sensei Biotherapeutics BioLineRx Gelteq Portage Biotech Matinas Biopharma (NYSE:MTNB) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk, community ranking and valuation. Do analysts recommend MTNB or PHXM? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Matinas Biopharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor MTNB or PHXM? In the previous week, PHAXIAM Therapeutics had 1 more articles in the media than Matinas Biopharma. MarketBeat recorded 1 mentions for PHAXIAM Therapeutics and 0 mentions for Matinas Biopharma. Matinas Biopharma's average media sentiment score of 0.00 equaled PHAXIAM Therapeutics'average media sentiment score. Company Overall Sentiment Matinas Biopharma Neutral PHAXIAM Therapeutics Neutral Does the MarketBeat Community believe in MTNB or PHXM? Matinas Biopharma and PHAXIAM Therapeutics both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformMatinas BiopharmaN/AN/APHAXIAM TherapeuticsN/AN/A Is MTNB or PHXM more profitable? PHAXIAM Therapeutics' return on equity of 0.00% beat Matinas Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Matinas BiopharmaN/A -123.06% -94.28% PHAXIAM Therapeutics N/A N/A N/A Which has more volatility and risk, MTNB or PHXM? Matinas Biopharma has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, suggesting that its stock price is 135% more volatile than the S&P 500. Which has better valuation & earnings, MTNB or PHXM? PHAXIAM Therapeutics has higher revenue and earnings than Matinas Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMatinas Biopharma$1.10M2.55-$22.94M-$4.85-0.11PHAXIAM Therapeutics$32.66M0.32-$240KN/AN/A Do institutionals & insiders hold more shares of MTNB or PHXM? 11.8% of Matinas Biopharma shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 6.0% of Matinas Biopharma shares are held by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryPHAXIAM Therapeutics beats Matinas Biopharma on 6 of the 10 factors compared between the two stocks. Remove Ads Get Matinas Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTNB vs. The Competition Export to ExcelMetricMatinas BiopharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$2.65M$6.76B$5.54B$19.48BDividend YieldN/A2.80%5.35%3.76%P/E Ratio-0.117.0923.4033.08Price / Sales2.55199.58369.3026.21Price / CashN/A65.6738.1617.55Price / Book0.125.966.624.56Net Income-$22.94M$142.11M$3.20B$1.02B7 Day Performance-1.25%-7.58%-5.00%-1.80%1 Month Performance-4.97%-12.54%-1.57%-4.05%1 Year PerformanceN/A-13.53%8.66%4.46% Matinas Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTNBMatinas BiopharmaN/A$0.55+6.0%N/AN/A$2.65M$1.10M-0.1130PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049MBRXMoleculin Biotech2.8979 of 5 stars$0.97-6.7%$17.33+1,686.9%-83.1%$10.53MN/A0.0020Gap UpBMRABiomerica0.9701 of 5 stars$0.57-2.5%N/A-33.1%$10.40M$5.58M-1.6760Positive NewsTRIBTrinity Biotech1.5803 of 5 stars$0.57-11.1%N/A-70.8%$10.29M$59.13M-0.25480Upcoming EarningsAnalyst ForecastGap UpNEUPNeuphoria Therapeutics Inc. - Common Stock1.81 of 5 stars$5.76+0.7%$21.00+264.6%N/A$10.12M$662,715.000.00N/AGap UpGOVXGeoVax Labs3.4551 of 5 stars$1.06-4.5%$14.20+1,239.6%-44.9%$10.00M$3.09M-0.1910Earnings ReportShort Interest ↓Analyst RevisionGap UpSNSESensei Biotherapeutics4.5513 of 5 stars$0.39-22.5%$4.25+978.7%-67.1%$9.91MN/A-0.3340Earnings ReportShort Interest ↓Gap DownHigh Trading VolumeBLRXBioLineRx2.6234 of 5 stars$2.96-3.0%$26.00+778.4%-91.5%$9.85M$21.99M-0.3440Analyst ForecastNews CoverageGap UpGELSGelteqN/A$1.04-1.0%N/AN/A$9.82MN/A0.00N/APRTGPortage Biotech0.9707 of 5 stars$9.25-3.6%N/A-25.3%$9.70MN/A-0.226Upcoming EarningsShort Interest ↓Gap Down Remove Ads Related Companies and Tools Related Companies PHXM Alternatives MBRX Alternatives BMRA Alternatives TRIB Alternatives NEUP Alternatives GOVX Alternatives SNSE Alternatives BLRX Alternatives GELS Alternatives PRTG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MTNB) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredOil Surge Predicted... But Are You Ready?Do you own oil and gas stocks? Or are you thinking about buying some? But it's NOT oil stocks, futures, or ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
